Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset

Neurogenetics

Volumn 14, Issue 3-4, 2013, Pages 173-179

  Ramos, Eliana Marisa ^a,b   Latourelle, Jeanne C ^c   Gillis, Tammy ^a   Mysore, Jayalakshmi S ^a   Squitieri, Ferdinando ^d   Di Pardo, Alba ^d   Di Donato, Stefano ^e   Gellera, Cinzia ^e   Hayden, Michael R ^f   Morrison, Patrick J ^g,y   Nance, Martha ^h   Ross, Christopher A ⁱ   Margolis, Russell L ⁱ   Gomez Tortosa, Estrella ^j   Ayuso, Carmen ^k   Suchowersky, Oksana ^l   Trent, Ronald J ^m   McCusker, Elizabeth ^m,n   Novelletto, Andrea ^o   Frontali, Marina ^p   Jones, Randi ^q   Ashizawa, Tetsuo ^r   Frank, Samuel ^c   Saint Hilaire, Marie Helene ^c   Hersch, Steven M ^a   Rosas, Herminia D ^a   Lucente, Diane ^a   Harrison, Madaline B ^s   Zanko, Andrea ^t   Abramson, Ruth K ^u   Marder, Karen ^v   Gusella, James F ^a,w   Lee, Jong Min ^a,w   Alonso, Isabel ^b,x   Sequeiros, Jorge ^b,x   Myers, Richard H ^c   MacDonald, Marcy E ^a,w   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PORTO   (Portugal)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d IRCCS NEUROMED   (Italy)

^e DEPARTMENT OF NEUROSURGERY   (Italy)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^h HENNEPIN COUNTY MEDICAL CENTER   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^k CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^l UNIVERSITY OF ALBERTA   (Canada)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ WESTMEAD HOSPITAL   (Australia)

^o UNIVERSITY OF ROME TOR VERGATA   (Italy)

^p INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^q EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r UNIVERSITY OF FLORIDA   (United States)

^s UNIVERSITY OF VIRGINIA   (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^v Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^w MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^x UNIVERSITY OF PORTO   (Portugal)

^y UNIVERSITY OF ULSTER   (United Kingdom)

more..

Author keywords

Dopamine pathway; Genetic modifiers; Glutamate receptors; Huntington's disease

Indexed keywords

DOPAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

3' UNTRANSLATED REGION; ARTICLE; COMT GENE; DAT1 GENE; DOPAMINERGIC SYSTEM; DRD2 GENE; DRD4 GENE; EXON; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GRIN2A GENE; GRIN2B GENE; HTT GENE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; NEUROTOXICITY; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR GENE; SYMPTOMATOLOGY; VARIABLE NUMBER OF TANDEM REPEAT;

AGE OF ONSET; CATECHOL O-METHYLTRANSFERASE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GENETIC ASSOCIATION STUDIES; HUMANS; HUNTINGTON DISEASE; NEURAL PATHWAYS; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84888063832     PISSN: 13646745     EISSN: 13646753     Source Type: Journal    
DOI: 10.1007/s10048-013-0364-y     Document Type: Article

References (39)

1. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72(6):971-983
2. Snell RG, MacMillan JC, Cheadle JP, Fenton I, Lazarou LP, Davies P, MacDonald ME, Gusella JF, Harper PS, Shaw DJ (1993) Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet 4(4):393-397. doi: 10.1038/ng0893-393
3. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, Folstein S, Ross C, Franz M, Abbott M et al (1993) Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 4(4):387-392. doi: 10.1038/ng0893-387
4. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA et al (1993) The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 4(4):398-403. doi: 10.1038/ng0893-398
5. Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, Marder K, Penchaszadeh G, Roberts SA, Gayan J, Brocklebank D, Cherny SS, Cardon LR, Gray J, Dlouhy SR, Wiktorski S, Hodes ME, Conneally PM, Penney JB, Gusella J, Cha JH, Irizarry M, Rosas D, Hersch S, Hollingsworth Z, MacDonald M, Young AB, Andresen JM, Housman DE, De Young MM, Bonilla E, Stillings T, Negrette A, Snodgrass SR, Martinez-Jaurrieta MD, Ramos-Arroyo MA, Bickham J, Ramos JS, Marshall F, Shoulson I, Rey GJ, Feigin A, Arnheim N, Acevedo-Cruz A, Acosta L, Alvir J, Fischbeck K, Thompson LM, Young A, Dure L, O'Brien CJ, Paulsen J, Brickman A, Krch D, Peery S, Hogarth P, Higgins DS Jr, Landwehrmeyer B (2004) Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 101(10):3498-3503. doi: 10.1073/pnas.0308679101
6. Gusella JF, MacDonald ME (2009) Huntington's disease: the case for genetic modifiers. Genome Med 1(8):80. doi: 10.1186/gm80
7. Djousse L, Knowlton B, Hayden MR, Almqvist EW, Brinkman RR, Ross CA, Margolis RL, Rosenblatt A, Durr A, Dode C, Morrison PJ, Novelletto A, Frontali M, Trent RJ, McCusker E, Gomez-Tortosa E, Mayo Cabrero D, Jones R, Zanko A, Nance M, Abramson RK, Suchowersky O, Paulsen JS, Harrison MB, Yang Q, Cupples LA, Mysore J, Gusella JF, MacDonald ME, Myers RH (2004) Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics 5(2):109-114. doi: 10.1007/s10048-004-0175-2
8. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 44(6):559-577
9. Vonsattel JP, DiFiglia M (1998) Huntington disease. J Neuropathol Exp Neurol 57(5):369-384
10. Tang TS, Chen X, Liu J, Bezprozvanny I (2007) Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosc Off J Soc Neurosci 27(30):7899-7910. doi: 10.1523/JNEUROSCI.1396-07.2007
11. Starling AJ, Andre VM, Cepeda C, de Lima M, Chandler SH, Levine MS (2005) Alterations in N-methyl-d-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. J Neurosci Res 82(3):377-386. doi: 10.1002/jnr.20651
12. Cepeda C, Ariano MA, Calvert CR, Flores-Hernandez J, Chandler SH, Leavitt BR, Hayden MR, Levine MS (2001) NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 66(4):525-539
13. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA (2002) Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33(6):849-860
14. Zeron MM, Fernandes HB, Krebs C, Shehadeh J, Wellington CL, Leavitt BR, Baimbridge KG, Hayden MR, Raymond LA (2004) Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol Cell Neurosci 25(3):469-479. doi: 10.1016/j.mcn.2003.11.014
15. Saft C, Epplen JT, Wieczorek S, Landwehrmeyer GB, Roos RA, de Yebenes JG, Dose M, Tabrizi SJ, Craufurd D, Arning L (2011) NMDA receptor gene variations as modifiers in Huntington disease: a replication study. PLoS Curr 3:RRN1247. doi: 10.1371/currents.RRN1247
16. Arning L, Saft C, Wieczorek S, Andrich J, Kraus PH, Epplen JT (2007) NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Genet 122(2):175-182. doi: 10.1007/s00439-007-0393-4
17. Arning L, Kraus PH, Valentin S, Saft C, Andrich J, Epplen JT (2005) NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. Neurogenetics 6(1):25-28. doi: 10.1007/s10048-004-0198-8
18. Andresen JM, Gayan J, Cherny SS, Brocklebank D, Alkorta-Aranburu G, Addis EA, Cardon LR, Housman DE, Wexler NS (2007) Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds. J Med Genet 44(1):44-50. doi: 10.1136/jmg.2006.045153
19. Ramos EM, Latourelle JC, Lee JH, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Marder K, Gusella JF, Lee JM, Alonso I, Sequeiros J, Myers RH, Macdonald ME (2012) Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset. Hum Genet 131(12):1833-1840. doi: 10.1007/s00439-012-1205-z
20. Warner JP, Barron LH, Brock DJ (1993) A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Mol Cell Probes 7(3):235-239. doi: 10.1006/mcpr.1993.1034
21. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR (1992) Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14(4):1104-1106
22. Biederman J, Petty CR, Ten Haagen KS, Small J, Doyle AE, Spencer T, Mick E, Monuteaux MC, Smoller JW, Faraone SV (2009) Effect of candidate gene polymorphisms on the course of attention deficit hyperactivity disorder. Psychiatr Res 170(2-3):199-203. doi: 10.1016/j.psychres.2008.12.016
23. Hamza TH, Chen H, Hill-Burns EM, Rhodes SL, Montimurro J, Kay DM, Tenesa A, Kusel VI, Sheehan P, Eaaswarkhanth M, Yearout D, Samii A, Roberts JW, Agarwal P, Bordelon Y, Park Y, Wang L, Gao J, Vance JM, Kendler KS, Bacanu SA, Scott WK, Ritz B, Nutt J, Factor SA, Zabetian CP, Payami H (2011) Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genet 7(8):e1002237. doi: 10.1371/journal.pgen.1002237
24. Tunbridge EM, Harrison PJ, Weinberger DR (2006) Catechol-o- methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 60(2):141-151. doi: 10.1016/j.biopsych.2005.10.024
25. Mannisto PT, Kaakkola S (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51(4):593-628
26. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 98(12):6917-6922. doi: 10.1073/pnas.111134598
27. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, Morris CM, Perry RH, Ferrier IN, Court JA (1997) D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7(6):479-484
28. Ritchie T, Noble EP (2003) Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 28(1):73-82
29. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, Syvalahti EK, Hietala J (1998) The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatr 3(3):256-260
30. Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P, Sedvall GC (1999) Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatr 4(3):290-296
31. Schoots O, Van Tol HH (2003) The human dopamine D4 receptor repeat sequences modulate expression. Pharmacogenomics J 3(6):343-348. doi: 10.1038/sj.tpj.6500208
32. van Dyck CH, Malison RT, Jacobsen LK, Seibyl JP, Staley JK, Laruelle M, Baldwin RM, Innis RB, Gelernter J (2005) Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med Off Publ Soc Nucl Med 46(5):745-751
33. van de Giessen E, de Win MM, Tanck MW, van den Brink W, Baas F, Booij J (2009) Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J Nucl Med Off Publ Soc Nucl Med 50(1):45-52. doi: 10.2967/jnumed.108.053652
34. Wersinger C, Chen J, Sidhu A (2004) Bimodal induction of dopamine-mediated striatal neurotoxicity is mediated through both activation of D1 dopamine receptors and autoxidation. Mol Cell Neurosci 25(1):124-137. doi: 10.1016/j.mcn.2003.10.002
35. Perez-Navarro E, Canals JM, Gines S, Alberch J (2006) Cellular and molecular mechanisms involved in the selective vulnerability of striatal projection neurons in Huntington's disease. Histol Histopathol 21(11):1217-1232
36. Fan MM, Raymond LA (2007) N-methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol 81(5-6):272-293. doi: 10.1016/j.pneurobio.2006.11.003
37. Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS, Landwehrmeyer GB, Myers RH, Macdonald ME, Gusella JF (2012) CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 78(10):690-695. doi: 10.1212/WNL.0b013e318249f683
38. McNicoll CF, Latourelle JC, MacDonald ME, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Saint-Hilaire MH, Massood T, Huskey KW, DeStefano AL, Gillis T, Mysore J, Goldwurm S, Pezzoli G, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH (2008) Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. Mov Disord 23(11):1596-1601. doi: 10.1002/mds.22186
39. Gusella JF, Persichetti F, MacDonald ME (1997) The genetic defect causing Huntington's disease: repeated in other contexts? Mol Med 3(4):238-246